CENTER FOR CANCER EXPERIMENTAL THERAPEUTICS

该提案的目标是在堪萨斯州建立一个“癌症实验治疗中心”。三个州立机构联合他们的资源和教员建立了一个中心，指导初级教员进行与癌症相关的研究，以及在化学和生物学之间进行实验所需的新基础设施。堪萨斯大学(KU)和堪萨斯技术企业公司(KTEC)提供的配套资金以及NIH-Cobre的支持将导致建立独特的核心设施，以确定将成为有用的基础生物医学研究工具的新型生物活性化合物和潜在的治疗剂。堪萨斯州在药物化学方面的强大传统，以及未来五年基础生物医学研究初级教员的扩张和离职关系，使堪萨斯州成为建立实验治疗学研究中心的合乎逻辑的地点。请拨资金支持五个项目，在这些项目中，初级教员和一名成功的高级教员以前没有得到国立卫生研究院的资助，他们担任私人投资。这些教员将与未来招聘人员的竞争力合作，并将建立一个获得大型设备和设施支持的竞争性计划。两个核心将由一群经验丰富的研究人员建立和运营，他们在组合化学、细胞和分子生物学、生物化学、癌细胞生物学以及化合物和细胞目标识别的新生物分析开发领域具有专业知识。产生和分析新化合物的专业知识，以及开发用于筛选的生物分析的专业知识相结合，为将两个研究领域结合为两个联合努力提供了独特的机会。这些中心将与新的初级教员合作，从国家癌症研究所储存库、来自商业来源的化合物库和现场生成的化合物库中筛选化合物库，以确定将加强其研究的试剂。

The goal of this proposal is to establish a "Center for Cancer Experimental Therapeutics" in the State of Kansas. Three state institutions combine their resources and faculty to establish a Center to mentor junior faculty in cancer-related research and novel infrastructure needed for experimentation at the interface between chemistry and biology. Matching funds provided by the University of Kansas (KU) and the Kansas Technology Enterprise Corporation (KTEC) together with NIH-COBRE support will result in the establishment of unique core facilities needed to identify novel bioactive compounds that will be useful basic biomedical research tools, and potential therapeutic agents. A strong tradition in medicinal chemistry at KU, relationships with expansion and turnover of junior faculty in basic-biomedical research over the next five years makes Kansas a logical site for establishing a Center for research in experimental therapeutics. Funds are requested for the support of five projects in which junior faculty and one successful senior faculty not previously funded by NIH serve as P.I.s. These faculty are partnered with competitiveness of future recruits, and a competitive program for the obtainment of large-scale equipment and facilities support will be established. Two Cores will be established and operated by an experienced group of investigators with expertise in the areas of combinatorial chemistry, cell and molecular biology, biochemistry, cancer cell biology, and the development of novel bioassays for compound and cellular target identification. The combination of expertise for the generation and analysis of novel compounds, together with that for the development of bioassays for screening, offers a unique opportunity for joining two research areas into two combined effort. The Cores will work with new junior faculty to screen compound libraries from the National Cancer Institute repositories, those from commercial sources, and those generated on-site, for identification of reagents that will enhance their research.